Recently, a EuroTransBio grant of €1.5 million has been awarded to a transnational consortium including ElexoPharm GmbH by the European Collaborative ETB program.
The project is a collaboration of ElexoPharm GmbH with SomantiX BV (Bilthoven, The Netherlands), VU University Medical Center (Amsterdam, The Netherlands), Saarland University (Saarbrücken, Germany) and PharmBioTec GmbH (Saarbrücken, Germany).
This subsidy is awarded for a period of three years and will allow the development of low molecular weight inhibitors of angiogenesis in colorectal cancer.
At ElexoPharm, lead finding and lead optimization based on molecular modelling, design and synthesis of biological active compounds, will be performed.
"ElexoPharm is very proud to have received this prestigious transnational grant to develop medicines to treat this disease of high medical need. It is a further recognition of the excellent drug discovery capabilities of our growing company", states Axel Koch, Managing Director of ElexoPharm.